Growth hormone replacement in patients with Langerhan's cell histiocytosis.

2.50
Hdl Handle:
http://hdl.handle.net/10541/92013
Title:
Growth hormone replacement in patients with Langerhan's cell histiocytosis.
Authors:
Howell, Simon J; Wilton, P; Shalet, Stephen M
Abstract:
OBJECTIVES: To assess the impact of growth hormone on growth and the underlying disease in children with growth hormone deficiency as a result of Langerhan's cell histiocytosis. STUDY DESIGN: Retrospective analysis of data from the Kabi (Pharmacia & Upjohn) international growth database (KIGS) for 82 children with Langerhan's cell histiocytosis treated with recombinant growth hormone. RESULTS: At the start of treatment the median (10-90th centile) age was 9.0 (5.2 to 14.7) years, with a median height standard deviation score (SDS) of -2.0 (-3.5 to -0.9). The median pretreatment height velocity (measured in cm/year) was 3.6 (0.9 to 6.4); this increased to 8.8 (3.8 to 12.0) in the first year of treatment with growth hormone, and then remained significantly greater than the pretreatment height velocity at 7.3 (4.4 to 9.7) and 7.1 (4.1 to 9.3) cm/year in the second and third years, respectively. The median height SDS increased from -2.0 to -0.8 (-2.3 to 0.6) by the end of three years of treatment. There was no increase in the recurrence rate of the underlying disease and no adverse event could be directly attributed to growth hormone treatment, apart from one case of benign intracranial hypertension that resolved on stopping treatment with growth hormone. CONCLUSIONS: Growth hormone replacement treatment for patients with Langerhan's cell histiocytosis with growth hormone deficiency is beneficial and safe.
Affiliation:
Department of Endocrinology, Christie Hospital NHS Trust, Withington, Manchester, UK.
Citation:
Growth hormone replacement in patients with Langerhan's cell histiocytosis. 1998, 78 (5):469-73 Arch. Dis. Child.
Journal:
Archives of Disease in Childhood
Issue Date:
May-1998
URI:
http://hdl.handle.net/10541/92013
PubMed ID:
9659097
Type:
Article
Language:
en
ISSN:
1468-2044
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Simon Jen
dc.contributor.authorWilton, Pen
dc.contributor.authorShalet, Stephen Men
dc.date.accessioned2010-02-12T15:05:09Z-
dc.date.available2010-02-12T15:05:09Z-
dc.date.issued1998-05-
dc.identifier.citationGrowth hormone replacement in patients with Langerhan's cell histiocytosis. 1998, 78 (5):469-73 Arch. Dis. Child.en
dc.identifier.issn1468-2044-
dc.identifier.pmid9659097-
dc.identifier.urihttp://hdl.handle.net/10541/92013-
dc.description.abstractOBJECTIVES: To assess the impact of growth hormone on growth and the underlying disease in children with growth hormone deficiency as a result of Langerhan's cell histiocytosis. STUDY DESIGN: Retrospective analysis of data from the Kabi (Pharmacia & Upjohn) international growth database (KIGS) for 82 children with Langerhan's cell histiocytosis treated with recombinant growth hormone. RESULTS: At the start of treatment the median (10-90th centile) age was 9.0 (5.2 to 14.7) years, with a median height standard deviation score (SDS) of -2.0 (-3.5 to -0.9). The median pretreatment height velocity (measured in cm/year) was 3.6 (0.9 to 6.4); this increased to 8.8 (3.8 to 12.0) in the first year of treatment with growth hormone, and then remained significantly greater than the pretreatment height velocity at 7.3 (4.4 to 9.7) and 7.1 (4.1 to 9.3) cm/year in the second and third years, respectively. The median height SDS increased from -2.0 to -0.8 (-2.3 to 0.6) by the end of three years of treatment. There was no increase in the recurrence rate of the underlying disease and no adverse event could be directly attributed to growth hormone treatment, apart from one case of benign intracranial hypertension that resolved on stopping treatment with growth hormone. CONCLUSIONS: Growth hormone replacement treatment for patients with Langerhan's cell histiocytosis with growth hormone deficiency is beneficial and safe.en
dc.language.isoenen
dc.subject.meshAdolescent-
dc.subject.meshBody Height-
dc.subject.meshChild-
dc.subject.meshChild, Preschool-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshGrowth Disorders-
dc.subject.meshHistiocytosis, Langerhans-Cell-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshPseudotumor Cerebri-
dc.subject.meshRetrospective Studies-
dc.titleGrowth hormone replacement in patients with Langerhan's cell histiocytosis.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital NHS Trust, Withington, Manchester, UK.en
dc.identifier.journalArchives of Disease in Childhooden

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.